Lønning PE - Search Results

1

Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ. Yates LR, et al. Among authors: lonning pe. Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22. Nat Med. 2015. PMID: 26099045 Free PMC article.

2

[Primary treatment of locally advanced breast cancer with neoadjuvant chemotherapy].

Aas T, Varhaug JE, Kolnes J, Søreide JA, Lønning PE. Aas T, et al. Among authors: lonning pe. Tidsskr Nor Laegeforen. 1994 Feb 28;114(6):668-70. Tidsskr Nor Laegeforen. 1994. PMID: 8191446 Norwegian.

3

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.

Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Aas T, et al. Among authors: lonning pe. Nat Med. 1996 Jul;2(7):811-4. doi: 10.1038/nm0796-811. Nat Med. 1996. PMID: 8673929

4

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome.

Aas T, Geisler S, Paulsen T, Børresen-Dale AL, Varhaug JE, Lønning PE, Akslen LA. Aas T, et al. Among authors: lonning pe. Acta Oncol. 1996;35 Suppl 5:5-8. doi: 10.3109/02841869609083960. Acta Oncol. 1996. PMID: 9142957

5

Molecular portraits of human breast tumours.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Perou CM, et al. Among authors: lonning pe. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093. Nature. 2000. PMID: 10963602

6

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL. Geisler S, et al. Among authors: lonning pe. Cancer Res. 2001 Mar 15;61(6):2505-12. Cancer Res. 2001. PMID: 11289122 Clinical Trial.

7

Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer.

Helle SI, Geisler S, Aas T, Paulsen T, Holly JM, Lønning PE. Helle SI, et al. Among authors: lonning pe. Br J Cancer. 2001 Jul 6;85(1):74-7. doi: 10.1054/bjoc.2001.1860. Br J Cancer. 2001. PMID: 11437405 Free PMC article.

8

The role of aromatase inactivators in the treatment of breast cancer.

Lønning PE. Lønning PE. Int J Clin Oncol. 2002 Aug;7(4):265-70. doi: 10.1007/s101470200038. Int J Clin Oncol. 2002. PMID: 12202980 Review.

9

Study of suboptimum treatment response: lessons from breast cancer.

Lønning PE. Lønning PE. Lancet Oncol. 2003 Mar;4(3):177-85. doi: 10.1016/s1470-2045(03)01022-2. Lancet Oncol. 2003. PMID: 12623363 Review.

10

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE. Aas T, et al. Among authors: lonning pe. Eur J Cancer. 2003 Mar;39(4):438-46. doi: 10.1016/s0959-8049(02)00732-3. Eur J Cancer. 2003. PMID: 12751373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

386 results

Search Page

Filters